La vendita allo scoperto per Oscar Health dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Oscar Health. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Oscar Health (NYSE:OSCR) Azioni, Report sulle vendite allo scoperto

Oscar Health

Oscar Health Inc is a health insurance company. The company provides various insurance plans for individuals, families, and employees. Also, the company provides virtual care, doctor support, scheduling appointments, and other related services. The company provides plans in the Medicare Advantage program to adults who are age 65 and older and eligible for traditional Medicare but who instead select coverage through a private market plan.

Market, Stock, Trading, Stocks, Markets shutterstock_2283804651

Equities

OSCR

Un&#39;azienda vede le sue azioni volare con guadagni impressionanti. Segnali cruciali indicano un potenziale di crescita ancora da esplorare.

Questo titolo è salito del 30% in 5 giorni e potrebbe non essere finita

Keybanc analyst Jason Celino maintains Cadence Design Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) with a Overweight and raises the price target from $340 to $358.

News

Price Target

Analyst Ratings

CDNS

Keybanc Maintains Overweight on Cadence Design Systems, Raises Price Target to $358

BLNK

Blink Charging And Axxeltrova Capital To Pursue £100M Special Purpose Vehicle

ZENA

ZenaTech Creates First Quantum Computing Prototype For AI Drone Solutions

Wells Fargo analyst Tiago Fauth downgrades Verona Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>) from Overweight to Equal-Weight and lowers the price target from $138 to $107.

Downgrades

VRNA

Wells Fargo Downgrades Verona Pharma to Equal-Weight, Lowers Price Target to $107

Goldman Sachs analyst James Schneider initiates coverage on Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) with a Buy rating and announces Price Target of $225.

Initiation

AMAT

Goldman Sachs Initiates Coverage On Applied Mat with Buy Rating, Announces Price Target of $225

<a href="https://investors.modernatx.com/news/news-details/2025/Moderna-Receives-Full-U-S--FDA-Approval-for-COVID-19-Vaccine-Spikevax-in-Children-Aged-6-Months-Through-11-Years-at-Increased-Risk-for-COVID-19-Disease/default.aspx" title="https://investors.modernatx.com/news/news-details/2025/Moderna-Receives-Full-U-S--FDA-Approval-for-COVID-19-Vaccine-Spikevax-in-Children-Aged-6-Months-Through-11-Years-at-Increased-Risk-for-COVID-19-Disease/default.aspx">https://investors.modernatx.com/news/news-details/2025/Moderna-Receives-Full-U-S--FDA-Approval-for-COVID-19-Vaccine-Spikevax-in-Children-Aged-6-Months-Through-11-Years-at-Increased-Risk-for-COVID-19-Disease/default.aspx</a>

MRNA

Moderna Receives Full FDA Approval for COVID-19 Vaccine, Spikevax, In Children Aged 6 Months Through 11 Years At Increased Risk For COVID-19 Disease

Macro Economic Events

Econ #s

Economics

USA Continuing Jobless Claims 1,965K Vs 1,980K Est.

Goldman Sachs analyst James Schneider initiates coverage on Amkor Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) with a Neutral rating and announces Price Target of $20.

AMKR

Goldman Sachs Initiates Coverage On Amkor Tech with Neutral Rating, Announces Price Target of $20

US Initial Jobless Claims 227K vs 236K Est.

Goldman Sachs analyst James Sheehan initiates coverage on GLOBALFOUNDRIES (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>) with a Neutral rating and announces Price Target of $40.

Goldman Sachs Initiates Coverage On GLOBALFOUNDRIES with Neutral Rating, Announces Price Target of $40

WIIM

HTOO

Fusion Fuel Green shares are trading lower after the company announced a 1-for-35 reverse stock split to regain Nasdaq minimum bid price rule compliance.

Goldman Sachs analyst James Sheehan initiates coverage on Western Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) with a Neutral rating and announces Price Target of $130.

Goldman Sachs Initiates Coverage On Western Digital with Neutral Rating, Announces Price Target of $130

D. Boral Capital analyst Jesse Sobelson maintains Vertical Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTL#NYSE">EVTL</a>) with a Buy and maintains $15 price target.

EVTL

D. Boral Capital Maintains Buy on Vertical Aerospace, Maintains $15 Price Target

PASG

Passage Bio shares are trading lower after the company announced a 1-for-20 reverse stock split.

Goldman Sachs analyst James Sheehan initiates coverage on Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Neutral rating and announces Price Target of $130.

Goldman Sachs Initiates Coverage On Micron Technology with Neutral Rating, Announces Price Target of $130

KLTO

Klotho Neurosciences shares are trading higher after the company announced the FDA has awarded orphan drug status for KLTO-202 for novel gene therapy in amyotrophic lateral sclerosis patients.

Goldman Sachs analyst James Schneider initiates coverage on Entegris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTG#NASDAQ">ENTG</a>) with a Neutral rating and announces Price Target of $85.

ENTG

Goldman Sachs Initiates Coverage On Entegris with Neutral Rating, Announces Price Target of $85

As JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) prepares to unveil its second-quarter earnings on July 15, the financial world is bracing for a significant shift that reflects broader economic trends. Over the past year, rising interest rates and inflationary pressures have squeezed borrowers and heightened market volatility, factors that are expected to dampen <a href="https://www.benzinga.com/quote/JPM/earnings">the bank&#8217;s profits.</a>
Analysts expect the company to report quarterly earnings at $4.47 per share, down from $6.12 per share in the year-ago period. JPMorgan projects to report quarterly revenue of $43.98 billion, compared to $50.2 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Wednesday, Truist Securities analyst John McDonald maintained a Hold rating on JPMorgan and raised the price target from $280 to $290.
With the recent buzz around JPMorgan, some investors may be eyeing potential gains from the company's dividends. As of now, JPMorgan offers an annual dividend yield of 1.98%, which is a quarterly dividend amount of $1.40 per share ($5.60 a year).
To figure out how to earn $500 monthly from JPMorgan, we start with the yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by JPMorgan's $5.60 dividend: $6,000 / $5.60 = 1,071 shares.
So, an investor would need to own approximately $303,264 worth of JPMorgan, or 1,071 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $5.60 = 214 shares, or $60,596 to generate a monthly dividend income of $100.
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
JPM Price Action: Shares of JPMorgan gained by 0.1% to close at $283.16 on Wednesday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46316741/top-3-risk-off-stocks-that-may-rocket-higher-in-q3">Top 3 Risk Off Stocks That May Rocket Higher In Q3</a></li>
</ul>
Photo: Rokas Tenys/Shutterstock

Earnings

Long Ideas

Dividends

Markets

Trading Ideas

How To Earn $500 A Month From JPMorgan Stock Ahead Of Q2 Earnings

D. Boral Capital analyst Jason Kolbert maintains NeuroSense Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRSN#NASDAQ">NRSN</a>) with a Buy and maintains $14 price target.

NRSN

D. Boral Capital Maintains Buy on NeuroSense Therapeutics, Maintains $14 Price Target

SAFX

XCF Global shares are trading higher after the company announced it will invest $1 billion in U.S. SAF plants.

Press Releases

Oscar Health Introduces a New Healthcare Experience to Individuals and Families in North Carolina

Oscar Health Announces Results for Third Quarter 2024

Oscar Health Announces New Health Insurance Options in New Jersey in 2025

Oscar Health, Inc. Announces that Mark Bertolini's Foundation Purchases Shares of Oscar Health

Oscar Health, Inc. 2024 Fourth Quarter and Full Year Earnings Conference Call

Oscar Health Announces Fourth Quarter and Full Year 2024 Results; Introduces Full Year 2025 Outlook

Oscar Health, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - OSCR

Ataraxis AI to Transform Precision Medicine in Cancer Care with $20.4 Million Series A

Oscar Health, Inc. 2025 First Quarter Earnings Conference Call

Oscar Health Announces Strong Financial Results for First Quarter 2025 And Reaffirms 2025 Guidance

Comments

Oscar Health

Vendite allo scoperto

Oscar Health (NYSE:OSCR) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO